Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs.
Immunoglobulins (IgG) as replacement therapy in primary antibody deficiencies can be given as intramuscular injections, or as intravenous or subcutaneous infusions. Our aims were to obtain information on the frequency of adverse systemic reactions during subcutaneous therapy, the occurrence and intensity of tissue reactions at the infusion sites, and serum IgG changes. Furthermore, we compared costs between the different replacement regimes. Our study included 165 patients (69 women, 96 men, aged 13-76 years) with primary hypogammaglobulinaemia or IgG-subclass deficiencies. Data were compiled from questionnaires filled in by the patients and from their medical records. 33,168 subcutaneous infusions (27,030 in home therapy) had been given. 106 (of which 16 were at home) adverse systemic reactions (100 mild, 6 moderate) were recorded in 28 patients (17%). No severe or anaphylactoid reactions occurred. Despite large immunoglobulin volumes given during 434 patient years (28,480 infusions), no signs have been found that indicate the transmission of hepatitis virus. Transient tissue reactions occurred at the infusion sites but were not troublesome to most patients and we found significant increases in mean serum IgG. The use of subcutaneous instead of intravenous infusions at home would reduce the yearly cost per patient for the health-care sector by US $10,100 in Sweden alone. We conclude that subcutaneous administration of IgG is a safe and convenient method of providing immunoglobulins. We were able to reach serum IgG concentrations similar to those by the intravenous therapy and we found that the method could also be used successfully in patients with previous severe or anaphylactoid reactions to intramuscular injections.
Department of Clinical Immunology, Karolinska Institute, Huddinge University Hospital, Sweden.
A
A
Gardulf
V
V
Andersen
J
J
Björkander
D
D
Ericson
S S
SS
Frøland
R
R
Gustafson
L
L
Hammarström
M B
MB
Jacobsen
E
E
Jonsson
G
G
Möller
D000293:Adolescent; D000328:Adult; D000361:Agammaglobulinemia / Q000628:therapy; D000368:Aged; D017074:Common Variable Immunodeficiency / Q000628:therapy; D003365:Costs and Cost Analysis; D005260:Female; D006699:Home Care Services; D006760:Hospitalization; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D007279:Injections, Subcutaneous / Q000009:adverse effects; D008297:Male; D008875:Middle Aged
D007074:Immunoglobulin G; D007136:Immunoglobulins